Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Public ClinicalTrials.gov record NCT00957905. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Non-randomized Phase 2 Study of Alvocidib (Flavopiridol) Plus Oxaliplatin With or Without 5-FU and Leucovorin for Relapsed or Refractory Germ-Cell Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial is studying alvocidib and oxaliplatin to see how well they work when given with or without fluorouracil and leucovorin calcium in treating patients with relapsed or refractory germ cell tumors. Drugs used in chemotherapy, such as alvocidib, oxaliplatin, fluorouracil, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving alvocidib together with oxaliplatin with or without fluorouracil and leucovorin calcium may kill more tumor cells.
Study identification
- NCT ID
- NCT00957905
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 36 participants
Conditions and interventions
Conditions
- Recurrent Extragonadal Seminoma
- Recurrent Malignant Extragonadal Germ Cell Tumor
- Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor
- Recurrent Malignant Testicular Germ Cell Tumor
- Recurrent Ovarian Germ Cell Tumor
- Stage III Testicular Cancer
- Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor
- Stage IV Extragonadal Seminoma
- Stage IV Ovarian Germ Cell Tumor
Interventions
- Alvocidib Hydrochloride Drug
- Fluorouracil Drug
- Leucovorin Calcium Drug
- Oxaliplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2009 (Type not available)
- Primary completion
- Aug 2014 (Actual)
- Completion
- Aug 2014 (Actual)
- Last update posted
- Mar 10, 2017
2009 – 2014
United States locations
- U.S. sites
- 10
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Tower Cancer Research Foundation | Beverly Hills | California | 90211-1850 | — |
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | — |
| USC / Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| University of California Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| University of Chicago Comprehensive Cancer Center | Chicago | Illinois | 60637 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| UPMC-Presbyterian Hospital | Pittsburgh | Pennsylvania | 15213 | — |
| University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh | Pennsylvania | 15232 | — |
| Riverview Hospital | Wisconsin Rapids | Wisconsin | 54494 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00957905, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 10, 2017 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00957905 live on ClinicalTrials.gov.